Other · developed by BioAge Labs
BGE-117 is an investigational drug studied in Anemia, Acute Posthemorrhagic Anemia.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05152641 | Phase 2 | Acute Posthemorrhagic Anemia | Withdrawn | BIOA |
| NCT04815603 | Phase 2 | Anemia | Withdrawn | BIOA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Posthemorrhagic AnemiaAnemia
See BIOA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BIOA catalysts and pipeline →